Show simple item record

Files in this item


Item metadata

dc.contributor.authorMcGhee, David
dc.contributor.authorParker, Alexander
dc.contributor.authorFielding, Shona
dc.contributor.authorZajicek, John
dc.contributor.authorCounsell, Carl
dc.identifier.citationMcGhee , D , Parker , A , Fielding , S , Zajicek , J & Counsell , C 2015 , ' Using 'dead or dependent' as an outcome measure in clinical trials in Parkinson's disease ' , Journal of Neurology, Neurosurgery, and Psychiatry , vol. 86 , no. 2 , pp. 180-185 .
dc.identifier.otherPURE: 242546265
dc.identifier.otherPURE UUID: 72f77e64-d266-4f32-a74e-0c9472760c22
dc.identifier.otherPubMed: 24854405
dc.identifier.otherScopus: 84921405698
dc.identifier.otherORCID: /0000-0003-3481-825X/work/64034663
dc.descriptionDM was funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Grant Reference Number RP-PG-0707-10124). The PINE study was funded by Parkinson’s UK (grant numbers G0502 and G0914), the BMA Doris Hillier Award, NHS Grampian Endowments, RS MacDonald Trust and SPRING (Special Parkinson’s Research Interest Group).en
dc.description.abstractBACKGROUND: Simple, robust, sensitive and clinically meaningful outcome measures are required for neuroprotective trials in Parkinson's disease (PD). We explored the feasibility of a composite binary outcome measure, 'dead or dependent', in such trials using data from a prospective follow-up study of an incident cohort of PD patients. METHODS: Two hundred incident patients had an annual follow-up, including assessment of the Hoehn-Yahr stage (H-Y) and Schwab and England Activities of Daily Living Scale (S&E). Annual scores were converted into binary variables (H-Y <3 vs H-Y ≥3, and S&E ≥80% vs S&E <80%). A new outcome of 'dead or dependent' was also created, with dependence in activities of daily living defined as S&E <80%. Using these data, sample sizes were calculated for a hypothetical three-year randomised trial in which the trial outcome was defined by a binary clinical variable, all-cause mortality, or PD-related mortality. RESULTS: At 3 years, 18.0% of patients were dead and 38.4% were dead or dependent. At 80% power, large sample sizes were required if PD-related mortality (n=1938 per study arm) or all-cause mortality (n=734) were used as the outcome, even for large treatment effects (30% reduction in relative risk). The new outcome of 'death or dependency' required the smallest sample sizes of all the outcome measures (n=277 for 30% reduction in relative risk, 627 for a 20% reduction). CONCLUSIONS: 'Death or dependency' is a feasible and potentially useful outcome measure in PD trials of neuroprotective agents, but further work is required to validate its use and define dependency.
dc.relation.ispartofJournal of Neurology, Neurosurgery, and Psychiatryen
dc.rightsThis is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.en
dc.subjectRC0321 Neuroscience. Biological psychiatry. Neuropsychiatryen
dc.subjectClinical Neurologyen
dc.subjectPsychiatry and Mental healthen
dc.subjectArts and Humanities (miscellaneous)en
dc.titleUsing 'dead or dependent' as an outcome measure in clinical trials in Parkinson's diseaseen
dc.typeJournal articleen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews.School of Medicineen
dc.description.statusPeer revieweden

This item appears in the following Collection(s)

Show simple item record